Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Karyopharm, Menarini Group receive positive CHMP opinion for NEXPOVIO » 08:47
05/20/22
05/20
08:47
05/20/22
08:47
KPTI

Karyopharm

$5.66 /

+0.24 (+4.43%)

Karyopharm Therapeutics…

Karyopharm Therapeutics and the Menarini Group, a privately-held, international pharmaceutical company, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of NEXPOVIO, a first-in-class, oral exportin 1 inhibitor, in combination with once weekly bortezomib and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received one to three prior lines of therapy. The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission makes a decision on Karyopharm's NEXPOVIO application. The EC's decision is expected within approximately 60 days following the CHMP recommendation. In December 2021, Karyopharm and Menarini Group entered into an exclusive license agreement to commercialize NEXPOVIO in Europe.

ShowHide Related Items >><<
KPTI Karyopharm
$5.66 /

+0.24 (+4.43%)

KPTI Karyopharm
$5.66 /

+0.24 (+4.43%)

04/11/22 Canaccord
Karyopharm price target lowered to $10 from $20 at Canaccord
02/09/22 JPMorgan
Karyopharm upgraded to Neutral from Underweight at JPMorgan
11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
KPTI Karyopharm
$5.66 /

+0.24 (+4.43%)

KPTI Karyopharm
$5.66 /

+0.24 (+4.43%)

KPTI Karyopharm
$5.66 /

+0.24 (+4.43%)

Recommendations
Benchmark says Emergent, Siga, Chimerix strength attributable to monkeypox scare » 08:38
05/20/22
05/20
08:38
05/20/22
08:38
EBS

Emergent BioSolutions

$31.67 /

+3.335 (+11.77%)

, SIGA

Siga Technologies

$8.64 /

+1.25 (+16.91%)

, CMRX

Chimerix

$2.20 /

+0.38 (+20.88%)

Benchmark analyst Robert…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SIGA Siga Technologies
$8.64 /

+1.25 (+16.91%)

EBS Emergent BioSolutions
$31.67 /

+3.335 (+11.77%)

CMRX Chimerix
$2.20 /

+0.38 (+20.88%)

EBS Emergent BioSolutions
$31.67 /

+3.335 (+11.77%)

05/04/22 Wells Fargo
Emergent BioSolutions price target lowered to $38 from $46 at Wells Fargo
04/29/22 Cantor Fitzgerald
Emergent BioSolutions downgraded to Neutral from Overweight at Cantor Fitzgerald
04/29/22 Cowen
Emergent BioSolutions price target lowered to $30 from $40 at Cowen
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
SIGA Siga Technologies
$8.64 /

+1.25 (+16.91%)

CMRX Chimerix
$2.20 /

+0.38 (+20.88%)

05/16/22 H.C. Wainwright
Chimerix price target lowered to $11 from $24 at H.C. Wainwright
12/22/21 H.C. Wainwright
Chimerix price target raised to $24 from $21 at H.C. Wainwright
11/22/21 H.C. Wainwright
Chimerix price target raised to $21 from $19 at H.C. Wainwright
06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
SIGA Siga Technologies
$8.64 /

+1.25 (+16.91%)

EBS Emergent BioSolutions
$31.67 /

+3.335 (+11.77%)

CMRX Chimerix
$2.20 /

+0.38 (+20.88%)

  • 15
    Sep
EBS Emergent BioSolutions
$31.67 /

+3.335 (+11.77%)

SIGA Siga Technologies
$8.64 /

+1.25 (+16.91%)

EBS Emergent BioSolutions
$31.67 /

+3.335 (+11.77%)

Hot Stocks
Kymera presents preclinical data on IRAK4 degrader KT-474 at SID meeting » 07:35
05/20/22
05/20
07:35
05/20/22
07:35
KYMR

Kymera Therapeutics

$14.88 /

-0.51 (-3.31%)

, SNY

Sanofi

$53.08 /

+0.665 (+1.27%)

Kymera Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNY Sanofi
$53.08 /

+0.665 (+1.27%)

KYMR Kymera Therapeutics
$14.88 /

-0.51 (-3.31%)

KYMR Kymera Therapeutics
$14.88 /

-0.51 (-3.31%)

05/04/22 B. Riley
Kymera Therapeutics price target lowered to $50 from $67 at B. Riley
04/28/22 Credit Suisse
Kymera Therapeutics initiated with an Outperform at Credit Suisse
03/10/22 JPMorgan
Kymera Therapeutics initiated with a Neutral at JPMorgan
02/10/22 Wells Fargo
Wells Fargo bullish on Kymera Therapeutics, initiates with an Overweight
SNY Sanofi
$53.08 /

+0.665 (+1.27%)

05/09/22 Wedbush
Wedbush downgrades Arvinas to Neutral, cuts price target to $43
05/02/22 Guggenheim
Sanofi price target raised to EUR 127 from EUR 121 at Guggenheim
04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
SNY Sanofi
$53.08 /

+0.665 (+1.27%)

KYMR Kymera Therapeutics
$14.88 /

-0.51 (-3.31%)

  • 01
    Jul
SNY Sanofi
$53.08 /

+0.665 (+1.27%)

SNY Sanofi
$53.08 /

+0.665 (+1.27%)

KYMR Kymera Therapeutics
$14.88 /

-0.51 (-3.31%)

Initiation
BofA starts TG Therapeutics at Underperform, sees difficult commercial setup » 07:06
05/20/22
05/20
07:06
05/20/22
07:06
TGTX

TG Therapeutics

$6.04 /

-0.06 (-0.98%)

BofA analyst Alec…

BofA analyst Alec Stranahan initiated coverage of TG Therapeutics with an Underperform rating and $5.00 price target. The stock is down 69% year-to-date since the announcement of voluntary withdrawals of U2 BLA and the terminated commercialization of Ukoniq, but ublituximab still faces 'difficult' commercial setup, the analyst tells investors in a research note. Stranahan adds that discounted pricing for the drug would be difficult as TG Therapeutics "struggles with cash", and the drug's one-hour infusion time is not a strong case for convenience.

ShowHide Related Items >><<
TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

06:13 Today BofA
TG Therapeutics initiated with an Underperform at BofA
04/19/22 B. Riley
TG Therapeutics application withdrawal 'clearing event,' says B. Riley
04/18/22 H.C. Wainwright
H.C. Wainwright keeps Buy rating on TG Therapeutics after Ukoniq withdrawal
03/09/22 H.C. Wainwright
TG Therapeutics' FDA committee timing within expectations, says H.C. Wainwright
TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

Initiation
TG Therapeutics initiated with an Underperform at BofA » 06:13
05/20/22
05/20
06:13
05/20/22
06:13
TGTX

TG Therapeutics

$6.04 /

-0.06 (-0.98%)

BofA analyst Alec…

BofA analyst Alec Stranahan initiated coverage of TG Therapeutics with an Underperform rating and $5 price target.

ShowHide Related Items >><<
TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

04/19/22 B. Riley
TG Therapeutics application withdrawal 'clearing event,' says B. Riley
04/18/22 H.C. Wainwright
H.C. Wainwright keeps Buy rating on TG Therapeutics after Ukoniq withdrawal
03/09/22 H.C. Wainwright
TG Therapeutics' FDA committee timing within expectations, says H.C. Wainwright
03/03/22 H.C. Wainwright
TG announced PDUFA goal date extension 'not a surprise,' says H.C. Wainwright
TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

TGTX TG Therapeutics
$6.04 /

-0.06 (-0.98%)

Yesterday
Hot Stocks
Mustang Bio announces updated interim data on XSCID treatment » 08:57
05/19/22
05/19
08:57
05/19/22
08:57
MBIO

Mustang Bio

/

+

Mustang Bio announced…

Mustang Bio announced that interim Phase 1/2 data on treatment with the same lentiviral vector used in MB-107, Mustang's lentiviral gene therapy for X-linked severe combined immunodeficiency, also known as bubble boy disease, in newly diagnosed infants under the age of two, support plans to initiate a multicenter pivotal Phase 2 trial for MB-107 under the Company's Investigational New Drug application in the second half of this year. Representing the largest cohort of infants with XSCID treated with gene therapy, the data include 23 infants with XSCID treated with the lentiviral vector at a median age of 3 months with a median follow-up of 2.6 years. Transduced autologous bone marrow CD34+ cells were generated for all patients with a median vector copy number of 0.81/cell and a median CD34+ cell dose of 9.61x106/kg. Prior to the infusion of cells, patients received busulfan targeted to a cumulative area-under-the-curve of 22 mg*hr/L. The treatment was well tolerated, and all patients experienced complete hematopoietic recovery. Severe adverse events occurred in three patients and all resolved. Seventeen patients had active infections prior to therapy, and in all cases these infections cleared. In addition, 15 patients have so far been able to discontinue intravenous immunoglobulin, and to date 14 patients have been successfully immunized. All patients are currently alive with stable vector marking in all cell lineages and without evidence of malignant transformation. The data, presented orally during the Clinical Trials Spotlight Symposium at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, are from a multicenter Phase 1/2 clinical trial underway at St. Jude, UCSF Benioff Children's Hospital in San Francisco and Seattle Children's Hospital. The lentiviral gene therapy is also being assessed in a Phase 1/2 clinical trial at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for XSCID patients who have been previously treated with hematopoietic stem cell transplantation and for whom re-treatment is indicated.

ShowHide Related Items >><<
MBIO Mustang Bio
/

+

MBIO Mustang Bio
/

+

01/24/22 B. Riley
Mustang Bio price target lowered to $6 from $13 at B. Riley
MBIO Mustang Bio
/

+

Hot Stocks
Allogene Therapeutics presents preclinical data on allogeneic CAR T cells » 08:48
05/19/22
05/19
08:48
05/19/22
08:48
ALLO

Allogene Therapeutics

$7.28 /

-0.32 (-4.21%)

Allogene Therapeutics…

Allogene Therapeutics will present preclinical findings evaluating the characteristics and function of donor-derived allogeneic CAR T cells. Data showed that cells from a diverse set of younger donors had improved characteristics and better in vitro anti-tumor activity compared to cells from older donors. The study also showed that cells from patients with certain cancers generally performed suboptimally based on functional assays and often could not be used to generate viable CAR T therapies. The findings will be presented during an oral session at the 2022 American Society of Gene and Cell Therapy Annual Meeting at 10:45am ET. The study evaluated the characteristics and performance of CAR T cells derived from healthy donors aged 19 to 62, comparing the healthy donor cells to those derived from patients with cancer. Based on the analysis, CAR T cells produced from younger donors had stronger T cell phenotypes and better in vitro anti-tumor activity cytotoxicity compared to older donors. The expression of specific exhaustion and activation markers was also correlated with increased donor age and in vitro anti-tumor activity decreased with donor age. Regardless of age, the CAR T cells derived from healthy donors performed better and had a lower manufacturing failure rate compared to those derived from patients with cancer. Creating allogeneic CAR T cells from healthy donors reduces product variability; reduces the risk of manufacturing failures; and enables treatment within days, eliminating the need for bridging chemotherapy. This study provides additional evidence that younger, healthy donors may improve product characteristics and potency compared to older donors. Allogene currently has four clinical programs underway investigating the potential of AlloCAR T product candidates for the treatment of relapsed/refractory large B cell lymphoma, RR multiple myeloma and advanced renal cell carcinoma.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$7.28 /

-0.32 (-4.21%)

ALLO Allogene Therapeutics
$7.28 /

-0.32 (-4.21%)

05/05/22 Raymond James
Allogene Therapeutics price target lowered to $13 from $36 at Raymond James
02/28/22 B. Riley
Allogene Therapeutics price target lowered to $21 from $30 at B. Riley
01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
ALLO Allogene Therapeutics
$7.28 /

-0.32 (-4.21%)

ALLO Allogene Therapeutics
$7.28 /

-0.32 (-4.21%)

Recommendations
X4 Pharmaceuticals price target lowered to $7 from $10 at B. Riley » 08:38
05/19/22
05/19
08:38
05/19/22
08:38
XFOR

X4 Pharmaceuticals

$1.10 /

-0.05 (-4.35%)

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani lowered the firm's price target on X4 Pharmaceuticals to $7 from $10 and keeps a Buy rating on the shares. While management's ability to address the longstanding balance sheet overhang remains a challenge, partly contributing to equity underperformance year-to-date, equity trades way below cash and heavily discounts the likelihood of success for three data catalysts and subsequent capital-efficient drug launch beginning in 2023, Mamtani tells investors in a research note.

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$1.10 /

-0.05 (-4.35%)

XFOR X4 Pharmaceuticals
$1.10 /

-0.05 (-4.35%)

05/13/22 H.C. Wainwright
X4 Pharmaceuticals price target lowered to $8.50 from $11 at H.C. Wainwright
04/05/22 Canaccord
X4 Pharmaceuticals price target lowered to $10 from $20 at Canaccord
03/17/22 Stifel
X4 Pharmaceuticals price target lowered to $10 from $19 at Stifel
12/16/21 B. Riley
B. Riley remains buyer of X4 Pharmaceuticals on weakness
XFOR X4 Pharmaceuticals
$1.10 /

-0.05 (-4.35%)

XFOR X4 Pharmaceuticals
$1.10 /

-0.05 (-4.35%)

Conference/Events
Maxim biotechnology analysts to hold an analyst/industry conference call » 04:55
05/19/22
05/19
04:55
05/19/22
04:55
CMRX

Chimerix

$1.82 /

+0.075 (+4.30%)

, KZIA

Kazia Therapeutics

$5.52 /

-0.2 (-3.50%)

Biotechnology Analysts,…

Biotechnology Analysts, along with Dr. Sabine Mueller a pediatric neuro-oncologist at the UCSF Brain Tumor Center, holds a panel discussion on new targets for pediatric brain cancer on an Analyst/Industry conference call on May 19.

ShowHide Related Items >><<
KZIA Kazia Therapeutics
$5.52 /

-0.2 (-3.50%)

CMRX Chimerix
$1.82 /

+0.075 (+4.30%)

CMRX Chimerix
$1.82 /

+0.075 (+4.30%)

05/16/22 H.C. Wainwright
Chimerix price target lowered to $11 from $24 at H.C. Wainwright
12/22/21 H.C. Wainwright
Chimerix price target raised to $24 from $21 at H.C. Wainwright
11/22/21 H.C. Wainwright
Chimerix price target raised to $21 from $19 at H.C. Wainwright
06/07/21 H.C. Wainwright
Chimerix price target raised to $19 from $18 at H.C. Wainwright
KZIA Kazia Therapeutics
$5.52 /

-0.2 (-3.50%)

10/14/21 Maxim
Kazia Therapeutics initiated with a Buy at Maxim
10/14/21 Maxim
Kazia Therapeutics initiated with a Buy at Maxim
CMRX Chimerix
$1.82 /

+0.075 (+4.30%)

  • 15
    Sep
KZIA Kazia Therapeutics
$5.52 /

-0.2 (-3.50%)

CMRX Chimerix
$1.82 /

+0.075 (+4.30%)

Wednesday
Hot Stocks
Scilex initiates Phase 2 study to evaluate safety, efficacy of SP-103 » 09:33
05/18/22
05/18
09:33
05/18/22
09:33
SRNE

Sorrento Therapeutics

$1.59 /

+0.14 (+9.69%)

, VCKA

Vickers Vantage Corp. I

$10.20 /

+ (+0.00%)

Scilex Holding Company…

Scilex Holding Company announced dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with acute LBP. Scilex's current marketed product, ZTlido, has label claims regarding superior adhesion qualities as compared to other products and SP-103 has the same adhesion characteristics. Scilex is developing SP-103 to be a triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP. Acute LBP can range in intensity from a dull, constant ache to a sudden, sharp sensation that leaves the person incapacitated. It is estimated that approximately 65 million adults in the U.S., or 25% of U.S. adults, suffer from acute back pain with a total potential global market opportunity of approximately $10.0 billion by 2026.

ShowHide Related Items >><<
VCKA Vickers Vantage Corp. I
$10.20 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

03/25/22 H.C. Wainwright
Sorrento Therapeutics price target lowered to $20 from $26 at H.C. Wainwright
12/28/21 H.C. Wainwright
H.C. Wainwright reiterates $26 target on Sorrento after Covistix news
08/09/21 H.C. Wainwright
Sorrento Therapeutics price target lowered to $26 from $30 at H.C. Wainwright
VCKA Vickers Vantage Corp. I
$10.20 /

+ (+0.00%)

VCKA Vickers Vantage Corp. I
$10.20 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$1.59 /

+0.14 (+9.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.